Clinical trials
Pembrolizumab clinical trials
Below are recruiting pembrolizumab clinical trials, each written for real people, not researchers. We’re tracking 603 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07061977RecruitingPhase 3
New cancer drug combo for advanced cervical cancer
This trial tests if giving the immunotherapy drug pembrolizumab before and after standard chemoradiation works better than the standard approach for people with high-risk cervical cancer that has spread locally.
Birmingham, AlabamaAges 18 years+ - NCT07619599RecruitingPhase 1
PET Scan to Track Lung Cancer Treatment Response
This study uses a special PET imaging scan to help doctors see how well pembrolizumab (an immunotherapy drug) is working against advanced non-small cell lung cancer. You'll receive the scan along with your regular pembrolizumab treatment and possible radiation therapy to help measure treatment response.
Duarte, CaliforniaAges 18 years+ - NCT05761223RecruitingPhase 1/Phase 2
Study of FB849 for adults with measurable cancer lesions
This early-stage trial tests whether FB849 is safe and tolerable, how the body handles it, and whether it shows any early signs of helping cancer. You may be able to join if you’re an adult with at least one measurable tumor spot and your health tests meet study requirements.
Cleveland, OhioAges 18 years+ - NCT06230471RecruitingPhase 2
Pembrolizumab plus lenvatinib or chemo for advanced bile duct cancer
This study tests whether adding another drug (lenvatinib or chemotherapy) to the immunotherapy drug pembrolizumab works better than pembrolizumab alone for advanced bile duct or gallbladder cancer that has not been treated before. It aims to find a more effective first treatment option.
Beijing, Beijing MunicipalityAges 18–80 - NCT05727904RecruitingPhase 3
New immunotherapy for advanced melanoma, with or without lifileucel
This trial studies whether adding lifileucel (a patient-specific immune-cell treatment) to pembrolizumab works better than pembrolizumab alone. It’s for people with untreated advanced melanoma that cannot be removed by surgery.
Birmingham, AlabamaAges 18–70 - NCT05980702RecruitingPhase 2
Comparing 2 vs 4 rounds of chemo-immunotherapy before surgery for head and neck cancer
This trial tests whether 2 or 4 cycles of pembrolizumab (immunotherapy) plus carboplatin and nab-paclitaxel (chemotherapy) before surgery works better for people with advanced head and neck cancer that can be removed. The goal is to see if fewer treatments are just as effective.
Guangzhou, GuangdongAges 18–75 - NCT06102395RecruitingPhase 3
Pembrolizumab plus chemo before surgery for advanced head and neck cancer
This trial tests whether adding pembrolizumab (an immunotherapy drug) to standard chemotherapy before surgery can help people with advanced head and neck cancer. It aims to see if the combination is more effective than chemotherapy alone.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06389422RecruitingPhase 2
Radiation plus Keytruda for liver cancer with vein clots
This trial tests a combination of moderate-dose radiation therapy and the immunotherapy drug pembrolizumab (Keytruda) for liver cancer that has spread into the main veins of the liver. It aims to see if this combination can shrink tumors and improve survival.
Beijing, Beijing MunicipalityAges 18–90 - NCT07811193RecruitingPhase 2
Study of new drug combined with immunotherapy for advanced bowel cancer
This trial tests a new drug (VVD-133214) combined with an existing immunotherapy (pembrolizumab) for advanced colorectal cancer that is mismatch repair deficient. It aims to see if the combination works better than pembrolizumab alone in shrinking or controlling the cancer.
Tucson, ArizonaAges 18 years+ - NCT07673887RecruitingPhase 3
Study of a new drug combo for advanced stomach cancer
This trial tests a new drug called ASP2138 combined with chemotherapy and pembrolizumab for people with advanced stomach or gastroesophageal junction cancer that cannot be removed by surgery or has spread. It may help if your tumor has certain markers (CLDN18.2 and PD-L1) and you haven't had prior chemotherapy for advanced disease.
Saint Louis Park, MinnesotaAges 18 years+ - NCT07660094RecruitingPhase 3
New treatment for advanced lung cancer that has stopped responding to immunotherapy
This trial tests a new investigational medicine (aglatimagene besadenovec) plus pembrolizumab against standard chemotherapy (docetaxel) for people with stage IV non-squamous lung cancer that has stopped responding to pembrolizumab. The new treatment is given as a tumor injection (like a biopsy) along with a pill (prodrug) and an infusion of pembrolizumab. The goal is to see if it can re-engage the immune system to fight the cancer.
New York, New YorkAges 18 years+ - NCT05185739RecruitingPhase 2
Pembrolizumab and lenvatinib before liver surgery for resectable cancer
This trial tests whether giving pembrolizumab (an immune therapy) and lenvatinib (a targeted pill) before planned liver surgery can improve outcomes for people with certain types of operable hepatocellular carcinoma (HCC). It’s meant for tumors that can be removed with curative intent, but still carry a risk of coming back.
BirminghamAges 18 years+ - NCT07283731RecruitingPhase 2
Testing zanzalintinib plus pembrolizumab for certain sarcomas
This trial is looking at whether a new combination of two drugs, zanzalintinib and pembrolizumab, can help people with certain types of advanced soft-tissue sarcoma that have not responded to other treatments. It aims to find out if the combination is safe and effective.
Houston, TexasAges 18 years+ - NCT07261683RecruitingPhase 2
Combination therapy for recurrent ovarian cancer
This trial tests a new combination of chemotherapy, immunotherapy, and a bladder relaxant for ovarian cancer that has come back after initial treatment. It aims to see if adding these drugs together can help control the cancer longer.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06502743RecruitingPhase 2
Study of chemotherapy and pembrolizumab with or without nesuparib for endometrial cancer
This trial tests a chemotherapy combination (carboplatin and paclitaxel) plus the immunotherapy drug pembrolizumab, followed by maintenance pembrolizumab either alone or with a PARP inhibitor called nesuparib. It is for women with advanced or recurrent endometrial cancer that is MMR-proficient (a type where the cells have a normal ability to fix DNA).
Kyeonggi-doAges 19 years+ - NCT07063745RecruitingPhase 2/Phase 3
Comparing a new drug combo for advanced lung cancer with a specific gene change
This trial tests a new drug called Navlimetostat combined with pembrolizumab and chemotherapy versus a placebo with the same standard treatments. It is for people with metastatic non-small cell lung cancer that has a specific missing gene (MTAP deletion) and who have not had prior treatment for their advanced disease.
Anchorage, AlaskaAges 18 years+ - NCT07027124RecruitingPhase 2
High-risk prostate cancer treatment before and after surgery
This trial tests a combination of hormone therapy, a targeted pill (Darolutamide), and an immunotherapy drug (Pembrolizumab) before and after surgery for men with high-risk prostate cancer that has specific genetic features. The goal is to see if this approach helps prevent the cancer from coming back.
New York, New YorkAges 18 years+ - NCT06952504RecruitingPhase 3
Comparing two drug combos for advanced endometrial cancer
This trial tests a new drug combination (sacituzumab tirumotecan plus pembrolizumab) against pembrolizumab alone for people with a specific type of advanced or recurrent endometrial cancer that has normal mismatch repair function. It aims to see which treatment works better.
Mobile, AlabamaAges 18 years+ - NCT05692999RecruitingPhase 3
Maintenance pembrolizumab dose study for non-squamous lung cancer
This Phase 3 trial tests two maintenance schedules (“usual” dose versus a lower dose) of pembrolizumab after your initial chemotherapy with pembrolizumab. It aims to see if the lower dose works well enough to control cancer while possibly reducing side effects.
NamurAges 18 years+ - NCT06875310RecruitingPhase 3
Study of adagrasib plus pembrolizumab plus chemotherapy for KRAS G12C lung cancer
This trial tests if adding the targeted drug adagrasib to standard immunotherapy and chemotherapy helps people with a specific KRAS G12C mutation in non-squamous non-small cell lung cancer that has spread. It is for people who have not had previous treatment for advanced disease.
Birmingham, AlabamaAges 18 years+ - NCT06793215RecruitingPhase 3
Divarasib plus pembrolizumab for KRAS G12C lung cancer
This trial compares a new targeted drug (divarasib) combined with an immunotherapy (pembrolizumab) versus standard chemotherapy plus immunotherapy for people with advanced lung cancer that has a specific KRAS G12C mutation. It aims to see if the new combination works better and is safe.
Anchorage, AlaskaAges 18 years+ - NCT05491083RecruitingPhase 1/Phase 2
Pembrolizumab plus ADG106 for advanced triple-negative breast cancer
This early-phase study tests pembrolizumab (an immune therapy) combined with ADG106 in people with advanced solid tumors, and specifically triple-negative breast cancer. It looks at whether the treatment can shrink tumors and improve outcomes for cancers that are progressing despite prior therapy.
SingaporeAges 21–99 - NCT06624644RecruitingPhase 2/Phase 3
LNS8801 with or without pembrolizumab for advanced melanoma
This trial tests a new drug called LNS8801, alone or with pembrolizumab, for people with advanced melanoma that has stopped responding to prior treatments, especially anti-PD-1 therapy.
Newport Beach, CaliforniaAges 18 years+ - NCT04295863RecruitingPhase 1
Test different dosing schedules for two immunotherapy drugs
This early trial compares how often two immune system medicines—nivolumab and pembrolizumab—are given for advanced or metastatic cancers. It aims to see which dosing interval is workable and safe for people needing treatment.
Chicago, IllinoisAges 18 years+
Hear when a new Pembrolizumab trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for pembrolizumab?
- Yes. Clin2 currently lists 603 recruiting pembrolizumab studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a pembrolizumab trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a pembrolizumab trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.